| Drug Class | Company | Drug Name | Alt Name | Drug Status | Notes | AIDS# |
| Biological Response Modifier | Hemispherx; Rega Institute For Medical Research | Atvogen™ | Ampligen, AMP, Poly(I)-Poly(C12U) | Phase II | Completed |
000136
|
| Entry and Fusion Inhibitors | Schering-Plough | Vicriviroc | SCH-417690, SCH-D, VCV | Phase III | Drug Development Halted as of July 15, 2010 due to poor performance |
210504
|
| Entry and Fusion Inhibitors | Rapid Pharmaceuticals | Adaptavir | RAP101; monomeric d-Ala-peptide T-amide (mDAPTA) | Phase II | Unknown |
052004
|
| Entry and Fusion Inhibitors | Pfizer | PF-00232798 | | Phase II | Completed |
|
| Entry and Fusion Inhibitors | Progenics Pharmaceuticals | PRO-140 | | Phase II | Ongoing |
088103
|
| Entry and Fusion Inhibitors | Genzyme Corporation | AMD-070 | AMD-11070 | Phase II | Completed |
495149
|
| Entry and Fusion Inhibitors | Sangamo BioSciences | SB-728 | CCR5-specific zinc finger protein nuclease | Phase I/II | Ongoing, Not Recruiting |
|
| Entry and Fusion Inhibitors | Bristol-Myers Squibb | BMS-663068 | BMS-626529 | Phase II | Recruiting |
|
| Entry and Fusion Inhibitors | Tobira Therapeutics | Cenicriviroc | TBR-652; TAK-652 | Phase II | Ongoing, Not Recruiting |
224423
|
| Entry and Fusion Inhibitors | Tanox; Biogen Idec; Taimed Biologies | Ibalizumab | TNX-355; Hu5A8 | Phase II | Invitation Only |
209859
|
| Entry and Fusion Inhibitors | Incyte Corporation | INCB-009471 | INCB-9471 | Phase II | Completed |
503495
|
| Histone Deacetylase (HDAC) Inhibitor | Abbott Labs | Epival™; Depakote™ | Valproic acid, Divalproex sodium, VPA | Phase II | Recruitment Unknown |
057177
|
| Histone Deacetylase (HDAC) Inhibitor | Merck | Zolinza™ | Vorinostat; MK-0683, Suberoylanilide Hydroxamic Acid (SAHA) | Phase II | Recruiting |
186714
|
| Integrase Inhibitor | Japan Tobacco Inc.; Gilead Sciences; GlaxoSmithKline | Elvitegravir | EVG, GS-9137, JTK-303 | Phase IIIb | Recruiting |
241767
|
| Integrase Inhibitor | GlaxoSmithKline | Dolutegravir | GSK1349572 | Phase III | Recruiting |
|
| Integrase Inhibitor | GlaxoSmithKline | GSK1265744 | S-265744 | Phase IIb | Recruiting |
|
| Integrase Inhibitor | Boehringer Ingelheim | BI-224436 | | Phase I | Withdrawn |
|
| Integrase Inhibitor | GlaxoSmithKline | GSK1247303 | | Phase I | Terminated |
|
| Microbicide | Uniroyal/Crompton Corp/Biosyn | UC781 | | Phase I | Completed |
029940
|
| Microbicide | Reprotect, Inc. | BufferGel™ | Carbomer 974P, Carbopol 974P, Carbopol polymer | Phase II | Completed |
180064
|
| Microbicide | Panacos Pharmaceuticals | Bevirimat | BVM, PA-457; MPC-4326 | Phase II | Completed |
028530
|
| Microbicide | Gilead Sciences | Tenofovir gel (GS-1278) | GS-1278; PMPA gel | Phase III | Recruiting |
021800
|
| Microbicide | Starpharma | VivaGel™ | SPL-7013 gel | Phase I/II | Completed |
223863
|
| Microbicide | Procept/Interneuron/Indevus | Pro-2000 | PRO-2000/5 | Phase III | Completed |
032942
|
| Microbicide | Population Council Center for Biomedical Research | Carraguard™ | Carragaen, Carrageenan gum, Carrageenin, Irish moss extract, PC-515 | Phase III | Completed |
000100
|
| Microbicide | Tibotec Pharmaceuticals | Dapivirine | TMC-120 | Phase III | Recruiting |
105293
|
| NNRTI | Merck & Co | MK-1439 | | Phase II | Recruiting |
|
| NNRTI | Kainos Medicine | KM-023 | | Phase I | Completed |
|
| NNRTI | Boehringer Ingelheim | BILR 355 BS | | Phase II | Terminated |
212773
|
| NNRTI | GlaxoSmithKline | GSK2248761 | IDX-899 | Phase II | On Hold |
|
| NNRTI | Pfizer | Lersivirine | UK453,061 | Phase II | Recruiting |
497274
|
| NRTI | Pharmasset/Dupont Pharmaceuticals; Vion | Reverset ™ | Dexelvucitabine; DFC | Phase II | Terminated |
000572
|
| NRTI | Biochem Pharma; Triangle Pharmaceuticals; Gilead Sciences | Amdoxovir | DAPD | Phase II | Completed |
005431
|
| NRTI | Achillion Pharmaceuticals | Elvucitabine | ACH-126443 | Phase II | Completed |
060327
|
| NRTI | Oncolys BioPharma | Festinavir | 4'-ethynyl-d4T; BMS-986001; OBP-601 | Phase IIb | Recruiting |
209894
|
| NRTI | Gilead Sciences | GS-7340 | Tenofovir Alafenamide (Prodrug of tenofovir) | Phase III | Recruiting |
046774
|
| NRTI | Glaxo Wellcome; GlaxoSmithKline; Pharmasset, Inc. | Racivir | RCV; (+/-)FTC | Phase II | Completed |
005245
|
| NRTI | Chimerix | CMX-157 | | Phase I | Completed |
477886
|
| NRTI | Koronis | KP-1212 | KP-1461(prodrug of KP-1212) | Phase II | Terminated |
|
| Other Immune Modulator | Hoffmann-La Roche | Pegasys™ | PEG IFN alpha-2a | Phase II/III | Ongoing |
|
| Other Immune Modulator | GlaxoSmithKline | Tucaresol | | Phase II | Completed |
029800
|
| Other Immune Modulator | BioMAS | AS-101 | Ammonium Trichlorotellurate | Phase I | Completed |
|
| Other Immune Modulator | Amgen | Enbrel™ | Etanercept; p75 TNFR-Fc fusion protein | Phase II | Unknown |
|
| Other Immune Modulator | Cytodyn, Inc. | Cytolin™ | | Phase II | Ongoing |
|
| Protease Inhibitor | Concert Pharmaceuticals | CTP-298 | C-10276, C-10297, C-10299 | Phase I | Completed |
|
| Protease Inhibitor | Tibotec Pharmaceuticals | TMC-310911 | | Phase II | Completed |
483146
|
| Unidentified | Merck & Co | MK-1972 | | Phase I | Terminated |
|